Why Life-Science Innovation is Politically Purple
June 28, 2016
![Stephen](https://cdn.sanity.io/images/03hnmfyj/production/7405b41ee3ca3c4657865e3dd9b9964dbff2c82d-1680x2100.jpg?rect=224,58,1233,1676&w=64&h=87&or=0&q=100&fit=clip&auto=format)
Stephen Ezell@sjezell
Vice President, Global Innovation Policy, and Director, Center for Life Sciences Innovation
Information Technology and Innovation Foundation
Speaker
On June 28, 2016, Stephen Ezell spoke at a Center Forward Congressional briefing on “Why Life-Sciences Innovation is Politically Purple,” explaining that U.S. leadership in global life-sciences innovation has resulted from a strong bi-partisan commitment to support robust levels of public investment in basic life-sciences research while creating an environment in which continued private-sector investment in drug discovery can flourish thanks to strong intellectual property protections and a drug pricing reimbursement system that permits reasonable profits to be reinvested in future generations of biomedical innovation.